focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Here is the AGM presentation for Atu027 Phase 2a Pancreatic Cancer Interim Analysis in case you missed it. http://silence-therapeutics-com.s3-eu-west-1.amazonaws.com/app/uploads/2014/09/Atu027-Phase-2a-Pancreatic-Cancer-Interim-Analysis.pdf
Yesterday the spread was 18% today it is down to a much more reasonable 4.65%. Lets hope the spread stays reasonable.
http://maynardpaton.com/2015/05/06/bioventix-67-margins-from-monoclonal-antibodies/#more-1713
Is this good for small shareholders?They are going to remain listed on the AIM. So the 15% buyback looks like it maybe good for small shareholders. Does anyone else have a opinion?
Will Alnylam Pharmaceuticals have to ask silence therapeutics for a RNAi trigger license for all of its therapeutics. This could be expensive for Alnylam Pharmaceuticals (the leader in the field, $9.8B market cap) and very lucrative for silence therapeutics! Milestones and royalties :), see the link http://rnaitherapeutics.blogspot.fi/2015/03/alnylams-scientifically-dishonest.html
Net Asset Value per Share up to 2.90p (a 7.25% increase) £1.32M gain on portfolio investments. cash balances of £6.29 million Looks good
Sarossa subscribed for 2,000,000 SLN shares, at 200p £4M on 10 April 2013. Now silence ther. worth 255p or £5.1M (profit of 1.1M). In addition to 343,053 options that converted to shares (at 233.5p) for the GVC investment that did not even go through a £801,029 profit. Net Asset Value per Share for last report of 2.69p, plus share a buy back. Why is Sarossa so under valued?
The last investment in PHC on the 8th Oct 2014 (459708 shares, price 69p) seems to have done well. The price of PHC is now 120p. Therefore for that specific investment a 57.5% increase occurred or £234,451 profit. In addition to the earlier placement of 3,377,596 shares at 78p (£2.63M). Now worth £4M, a £1.42M increase.
Close Brothers Asset Management have just announced that they have a 8% stake.
Considering how Abcam have risen and risen and risen (to the ridiculous valuation now). I think Bioventix could have a few positive years ahead. It is a conservatively run company, low CAPEX, lots of cash in the bank and 4 years of high ROCE >40% and high operating margins and a good dividend on top. Bioventix have specialized towards targeting small molecules rather than proteins like Abcam. They are also targeting there antibodies to the automated diagnostic market which takes a long time to validate with the individual machine and is therefore less likely to be replaced with cheaper antibody.
Sarossa have decided to buy more PHC shares at a inflated price of 118p (Liberum Capital give a fair value of 75p for PHC). http://www.investegate.co.uk/plant-health-care--phc-/rns/tr-1--notification-of-major-interest-in-shares/201412151351327825Z/
QPI-1002 misses the phase II predefined 30% improvement (only 15%), except in subgroups. It is unsure if they will go through to pIII. Still it shows that silence therapeutics core chemistry/products do something. Quark only used naked siRNA, whereas silence use lipid coating which should improve the effect. http://www.fiercebiotech.com/story/quarks-rnai-treatment-misses-mark-phase-ii-kidney-trial/2014-07-29
Here is new poster of Atu111 (siRNA against Ang2) in lung sepsis which silence are developing. It looks promising. http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCIQFjAA&url=http%3A%2F%2Fsilence-therapeutics.com%2Fwp-content%2Fuploads%2F2011%2F12%2FPoster-GRC-Ang2-siRNA.pdf&ei=t_vXU727GOvNygOu24HoBA&usg=AFQjCNFZ8c_ORb7-cCCOl-SIk6fgCaWK6Q&sig2=YEd0R23TZAmB1Hr9pXGl2w&bvm=bv.71954034,d.bGQ&cad=rja
World Transplant Congress 2014 Abstract for QPI-1002 from licence Quark pharma (which Silence ther. gets royalties from) looks to be positive for phase 2 according to the congress abstract. Abstract# 2967. http://onlinelibrary.wiley.com/doi/10.1111/ajt.12880/pdf Royalty and milestone deal details are not announced. It could be as high a £4M milestone upon entering phase 3. If the agreement is similar to Quarks other licensed siRNA PF-655 with Silence ther.
Here is a article discussing PF-655 from Quark pharma in phase II (diabetic macular edema) expected to be announced in 1-2months time. If it is successful, Silence therapeutics gets a £4M milestone payment (plus higher milestone payments at phase III, and sales royalties). I think it's second attempt at a higher dose (3mg) may be successful. http://www.fool.com/investing/general/2014/03/19/why-pfizer-investors-should-watch-quark-this-summe.aspx
Quark pharma successfully complete phase II trial (delayed graft function using AtuRNAi-enabled QPI-1002. Which means royalty payments for silence therapeutics (AtuRNAi developed and licenced by silence) at some point. http://www.marketwatch.com/story/quark-announces-completion-of-phase-ii-trial-evaluating-qpi-1002-for-prevention-of-delayed-graft-function-in-kidney-transplant-patients-2014-07-01
Interesting piece on silence therapeutics IP on RNAi trigger mechanisms http://rnaitherapeutics.blogspot.fi/2014/07/rnai-trigger-history-revisited-as.html
"The Options were granted at market price on the date of their respective grants, but with a dividend credit mechanism which adjusted the Options' exercise prices relative to all dividends declared by GVC from the date of the grants up until exercise. The Options' average exercise price is therefore approximately £1.89 per share. " For very little work/risk Sarossa plc have now banked a cool £1.49M worth of shares :) http://www.investegate.co.uk/gvc-holdings-plc--gvc-/rns/exercise-of-share-options/201406260700065560K/